Priothera closes 30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Financing to advance mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, and potential best-in-class therapy for AML patients
DUBLIN, Oct. 12, 2020 -- (Healthcare Sales & Marketing Network) -- Priothera Limited, a clinical stage company... Biopharmaceuticals, Oncology, Venture Capital, Personnel Priothera, mocravimod, sphingosine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Marketing | Pharmaceuticals | Venture Capital